Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form 8-K current report filed with the SEC, notifying investors of the issuance of a press release for first-quarter financial results and providing an exhibit reference. It does not contain the actual earnings data or financial statements itself, nor is it a full quarterly or annual report, call transcript, or any other specific event category. As a generic SEC current report without substantive financial content beyond a press‐release reference, it falls under the general regulatory filings category.
2026-05-08 English
10-Q - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-08 English
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filing describing Item 5.07 “Submission of Matters to a Vote of Security Holders” for Atossa Therapeutics’ 2026 Annual Meeting. It provides detailed vote counts for director elections, ratification of auditors, a reverse stock split amendment, and an advisory vote on executive compensation. This corresponds to an official announcement of shareholder voting results, matching the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-08 English
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 13, 2026. It announces a Settlement Agreement resolving patent disputes related to intellectual property and PTAB proceedings. The content focuses on legal and strategic developments rather than financial results or management changes. It does not contain financial statements or detailed financial data. The document is a regulatory announcement about a legal settlement and related events. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-16 English
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
Director's Dealing
2026-03-31 English
10-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
Annual Report FY 2025
2026-03-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.